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Psoriatic patients have a decreased proportion of mono-
cytes expressing class II major histocompatibility complex 
antigens (DR + monocytes) in their peripheral blood . The 
expression of the DR antigen on monocytes after culture 
in the presence of either autologous lymphocytes (endog-
enous interferon-gamma, IFN--y) or exogenous IFN--y was 
inves tigated . In normal AB serum the lymphocytes of the 
maj ority of the patients showed a spontaneous IFN--y pro-
duction which was sufficient for DR antigen induction , 
while the monocytes displayed approximate normal sus-
R ecently, much attention has been focused on the fac t that interferon (IFN) regulates the expression of his-tocompatibility antigens (MHC antigens) in severa l cell types [1 ,2]. It has been shown that the expres-sion of class II MH C antigens on J11 onocytes/ m ac-
rophages, a feature critical to the antigen-presentin g fun ction of 
these cells, is regulated by IFN-y [2,3]. 
In psoriasis, several abnorm al functions of immune cells similar 
to those found in patients suffering from the classical autoimmune 
diseases, have been described [4-6]. Recently, IFN-like activity 
has been detected in suction blister Auid from lesions [7] and in 
the peripheral blood [8] of patients suffering from psoriasis. Sim-
ilar findings have been published for systemic lupus erythema-
tosus [9]. Furthermore, we have foun d that the mitogen-induced 
production of IFN-y by peripheral blood cells of the patients, 
was significantl y reduced , and som e of these patients failed com -
pletely to produce IFN-y in vitro [4], as did patients suffering 
from several autoimmune diseases [5]. This prompted us to look 
for the class II MHC (DR) antigen expression in the peripheral 
blood monocytes both in vivo and in vitro after cultivation in 
the presence of added IFN-y. 
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MHC: major histocompatibility complex 
PBS: isotonic buffer sa line 
PGE: prostaglandin E 
SIRS: soluble immune response suppressor 
SOD: superoxide dis mutase 
ceptibility to exogenous IFN--y as judged by DR antigen 
expression . However, the sera of psoriatic patients con-
tained one or more factors that interfered with the IFN--y-
mediated DR antigen expression on cultured monocytes of 
the same patients. Res toration of IFN--y-induced DR an-
tigen expression on monocytes in the presence of the pa-
tient's sera was achieved by the addition of superoxide 
dismutase, 2-mercaptoethanol, or indomethacin. The clin-
ical signifi cance of these observations is discussed. J Invest 
DermatoI87:524-527, 1986 
Our findings, described in this paper, show that patients suf-
fering from psoriasis have a decreased proportion of DR + mono-
cytes in their periphera l blood . Three explanations are proposed 
for our observation: (1) diminished IFN-y production by patients' 
lymphocytes; (2) impaired susceptibility to IFN-y; and (3) the 
existence of soluble factors that inhibit the action of IFN-y on 
monocy tes. T he results suggest that the third possibility is most 
likely to be true. 
MATERIALS AND M ETHODS 
Patients The heparinized blood was obtained from hospital pa-
tients with exacerbating psoriatic lesions. Blood samples were 
drawn before the patients had undergone any internal therapy or 
PUV A treatment. H ealthy volunteers matched for age and sex 
were used as controls. 
Preparation of Monocytes T he mononuclear cells were iso-
lated from hepa rinized blood samples by density gradient cen-
trifugation as described [1 0]. The cells were resuspendend in cul-
ture medium RPMI-1 640 (Sifin , Berlin , G .D.R.), supplemented 
with L-glutamine 2 mM, penicillin 100 U / ml , streptomycin 100 
ILg/ml , and 10% hea t- inact iva ted AB serum or fetal calf serum 
(FCS) . FCS-coated glass coverlips were placed in Petri dishes and 
overlaid with the cell suspension (5 X 106/ ml) . After incubation 
at 37°C for 2 h , the nonadherent cell s were rem.oved by repeated 
washing with prewarmed m edium (6-8 times). T he coveriips 
with the adherent cells were either assayed immediately or in-
cubated further in 2 ml of fresh culture medium in Petri dishes; 
th e adherent cells consisted of more th an 93% m onocytes char-
ac terized by nonspecific esterase and Auorescence staining using 
a monoclonal antimonocyte antibody (BL-M/G). Less than 3% 
ofT lymphocytes, as assayed by stainin g with a m onoclonal pan-
T cell an tibody (BL-T2) , were usuall y observed am ong the ad-
herent cells. One to four days later, the number of adh erent cells 
dropped by an average of only 10-15% . During cultivation, a 
part of the adherent cells acquired the m o rphologic appearance 
of m ature large " histiocy te-like" cells. After 3 days in culture, 
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the ad herent cells displayed onl y a minimal contaminat ion by 
cells other than monocytes/macro phages (th ey were mo re than 
98% BL-M/G) , and no T lymphocytes co uld be detected . 
Surface Antigens Prior to the stainin g of cell s, the medium 
was asp irated and replaced by 1 % parafonnaldehyde solu tion fo r 
15 min at rQom temperature. T he cell s were then was hed twi ce 
and overl aid w ith isotoni c buffer so lution (PBS) con tainin g 2% 
bovine serUJ11 albLlmin. Afte r 15 min th e so lu tion was removed 
and · the cells were incubated w ith the app ropriate monoclonal 
antibo dies . After was hin g, th e coverslips were ihcubated w ith a 
fluoresce in-conju ga ted goa t an ti mouse antiserum di luted 1: 40 in 
PBS . T he cell s wer<~ then studi ed und er a Ruo rescent microsco pe 
Oenalum ar, Ca rl-Zeiss Jena, G .D.R.) . At leas t 200 cells were 
counted each tim e. 
Monoclonal Antibodies (Mab) T he data of the utilized Mab 
have been described in detail elsewhere [11 ,12]. B ri eRy, BL-T2 
is a pan-T cell Mab (CD-5 cluster) , and the M ab BL-M /G is 
directed against all monocytes, g ranul ocy tes , and a proportion of 
the null cells. THree different M ab recog nizing 110npolymorp hi c 
- determinants of class II MHC antigens (here called DR) were 
used: BL-l al1 [1 2j , VID-1 (kindly provided by Prof. Knapp, 
Vienna), and ant i- HLA-DR (Becton-D ickinso n). 
Interferon Semi purifi ed lFN-y (Paesel, Frankfurt , F.R.G.) 
havi ng lOu IU / mg protein and seql ipurified IFN-a, 10(' IU / m g 
protein (a gift by Prof. Ca tltell , Hel sinki), were used . [n so me 
experi ments purifi ed reco mbinant human lFN-y (Genentech), 3 
X ]07 IU/ m g protein, was used with the sa me results. 
Supplements Superoxide dismutase (SOD) was prepared from 
human ery throcy tes (kindly provided by Dr. H ornig, D essau). 
/3-Carotene was obtained from Hoffmann-La R oche as Phenoro 
capsules containing 10 m g {3-ca ro tene and 15 m g canthaxa nthin e. 
RESULTS 
DR Antigen Expression. on Monocytes In Vivo Peripheral 
blood m onocy tes were isolated w ith the ad herence technique and 
immed iate ly tested for their DR anti gen express ion by severa l 
Ma b directed against class II MH C. As shown in Fig 1, the pro-
porti on of DR .,. monocy tes in th e g roup of pso riatic patients was 
signifi cantl y lower than in tht norm al 'controls (p < 0.01). T he 
results from the tests w ith all 3 Mab were comparable (onl y the 
res ults with V ID-l are shown). T he mean percenta ge of DR + 
ceHs fro m 31 norm al volun teers was 59%, ran ging from 35- 81 %. 
Only 6 'of21 patieilts showed a DR expression w ithin this no rm al 
ran ge. The mea n va lue o f the 21 pat ients was 30%, rangin g from 
12-55%. 
Interferon-Gamma Production by Lymphocytes In Vitro 
We have .shown that peripheral blood mononuclea r cells of pso-
riatic patients have a red uced in vitro respo nse to conca navalin A 
and phytohemagglutinin , as meas ureed by IFN- y prod uction 17 J. 
However, very small doses of IFN-y are necessa ry for the in-
ducti o~l of DR an tigens on J11 onocy tes (i n vitro: as low as 1 IU/ ml) 
[2,3J. T hus the antiviral assay is not sensitive enough to determine 
w hether lymphocy tes are able to produce suffic ient amounts of 
IFN-y for DR antigen induction on monocy tes. Recentl y, we [3J 
and others [2] were able to show that h.ighl y purified 111 0nocytes 
expressed progress ively fewer DR anti gens after 2-3 days o f cul-
ture. T he addition of either a low dose of IFN-y (exogenous IFN-
y) or autologous Iymphocyt.es (endogenous IFN -y) to the mono-
cytes prevented this .J oss of DR anti gens. T he rei ndu ction of DR 
antigen ex pression in th e presence of auto logous lym phocy tes 
was abrogated by anti-IFN-y antibod ies o r cyclosporine A, in-
dicating that IFN-y produ ced spontaneously by the lymphocy tes 
is the active mediator in this very sens.itive assay. In the aptiviral 
assa y usually o nl y marg inal amounts of lFN acti vity «10 IU / m l) 
in these supernata nts are detectable. We have cultured 105 mono-
cytes of health y donors o r psori atic pati ents in the presence or 
absence of 5 x 10· auto logous lymphocytes in culture medium 
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Figure 1. Propo rti on o f DR + 111 0nocy tcs reco rded imm ediatcly aftcr 
separatio n fro m the peripheral b lood . Bars, mean ± SO. 
containing 10% AB serum for 3 days. Therea fter, the DR antigen 
expression on 1110nocy tes was determined. As shown in Table I, 
the Iy mphocyt.es of the majority of the pati ents produced suffi -
cient amounts o fIFN-y for conservation of DR antigen express ion 
on cultured monocytes. Onl y 3 of8 pati ents showed a decrcJsed 
spontaneous IFN-y produ ction in thi s assay. T herefore, it seems 
unlikel y th at a d iminished IFN-y produ ction is the so le reason 
for t he decreased DR antigen ex pression on monocytes o f pso-
natl c patIents 111 V I VO . 
Susceptibility to IFN-y In Vitro The percen ta ge of 111 0no-
cytes ex pressing DR anti gehs decreased within 3 days of culture 
both in hea lth y donOl's and pso riatic pati ents. When 10 IU / ml 
Table I. Spontaneo Lls IFN- y Produ ction by Lyil1phocytes As 
Judged by DR Anti gen Expression on Autologous M onocytes 
A fter Co-cuI tu re 
Supplem cnt 
N o ne 
IFN- y (5 IU / ml) 
Auto logous 
I ym phocytes 
Anti-IF N-yand 
auto logous 
lymphocytes 
Perccnt DR + Mo nocytcs 
o f Hea lth y Donors 
18 (5)" 
63 (7) 
60 (8) 
25 (7) 
Pso ria tic Patients 
16 (5) 
58 (8) 
48 (15) 
NOh 
Highl y purifi ed monocy tes (IO'/wel l) were cultured in mediulll \vith iO% All 
serulll and va rio us supplements for 3 days; therea fter. the DR antigen e.'press ion 
on lhe 1ll0 1l0C)' t c s was determined . In the absen ce o r :ll1y IFN-y a slope in Dn 
anti gen expression was observed. In the presence o f either 5 IU / IlIII FN--y (exogelWus 
IFN --y) o r 5 X 10' all to logous lymphocytes per well (endogeno us IFN--y) the loss 
o f D R a/!l igens was prevented. The DR anti gen- preserving effect o f added lym-
phocy tes is caused by spontaneous IFN- y synthesis. because a Mab aga inst IFN--y 
was able to abolish this effecl. 
"Mean (SO). n = 8. 
'Not dOlle. 
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IFN-y was added to cu ltures containing AB seru m, the values 
remained significan tl y higher in bo th groups (Fig 2a), w hereas 
IFN-O' (1-500 IU / ml) addition had no effect (not shown). T he 
margina l difference between the health y group (68 ± 8%) and 
the patient group (56 ± 11 %) was not signifi cant (p > 0.05). 
Th us, the susceptibili ty of patients' monocytes to IFN- y with 
regard to DR anti gen ind uction seems to be normal. However, 
as shown in Fig 2b, the action of IFN-y was prevented by au-
tologous serum (10%) in 10 of 12 patients (24 ± 13% ). This 
inhibito ry act ivity in the patients' sera was not geneticall y re-
stricted since sera of psoriatic patients also reduced the DR antigen 
exp ression on several allogeneic monocytes (not shown) . H ow-
ever, the IFN-y effect on monocytes of heal th y dono rs was rarely 
inAuenced by the sera of patients; in onl y 3 of 12 hea lthy donors 
the proportion of DR + monocytes was signifi can tly decreased by 
sera of patients in the presence of IFN-y. T he mean value of DR + 
monocytes of healthy donors in th e presence of both IFN-y and 
sera of patients was 58 ± 12%, that is, 15% inhibition vs 57% 
inhibition in the group of psoriatic patients (p < 0.01). 
Characteristics of the Inhibitory Activity in the Sera of 
Psoriatic Patients It has been shown that prostaglandins (PG) 
of the E series inhibit the IFN-y effect on class (( MHC antigen 
expression on rnonocytes/macrophages [1 ,13]. Furthermore, we 
have demonstrated that reactive oxygen intermediates induced by 
phagocytosis also red uced the DR antigen expression on mono-
cytes 11 31. We tested whether the inhibitory activity in the sera 
of patients cou ld be abolished by the addition of reducing agents 
such as 2-mercaptoethanol, scavengers of reactive oxygen inter-
mediates such as SOD and /3-ca rotene, o r the inhibitor of PGE 
synthesis , indomethacin. 
As shown in Tab le II, the inhibitory effect of the sera of psoriati c 
patients on the If N-y-mediated DR anti gen expression ca n be 
prevented by SOD, 2-mercaptoethanol, an.d indo meth acin. 
Studies on the kinetics of the DR antigen suppression by these 
sera revealed tl"\at w hen sera of psoriatic patients were added to 
the monocyte cu ltu res 1 day latq than IFN-y, no suppressive 
effect was observed (data not shown) . 
D ISC U SSIO N 
Peri phera l blood monocyte;; from patients suffering fro m pso-
rias is expressed fewer DR antigens on their surfaces than mono-
cytes from hea lthy donors (Fig 1). In order to explain this, we 
a b 
10 
IFN-r 
(lOU/mil 
. control 
Figure 2. Susceptibility of monocytcs to IFN-y in vitro. a, Monocytes 
of heal thy donors and psoriatic patients were cultured for 3 days in normal 
A B serum in the presence or absence ofIFN--y. Thereafter, thc DR antigen 
expression was determined. b, Monocytes of hea l thy donors and psoriatic 
patients were cultured for 3 days in autologous serum in the presence or 
absen ce of IFN--y. Thereafter, the DR antigen expression was determined. 
White bars, psoriatic patients (meal! ± SO, I! = 12) . Black bars, health y 
donors (mcan ± SO, n = 12). 
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Table II. Abolishment of the Inhibito ry Activity in Sera of 
Psori ati c Patients by Superoxide Dismutase (SOD). 
2-Mercaptoethanol. and Indomethacin 
Serum Supplement DR " Monocytes (%) 
AB Serum None 72 (10)" 
Pso riatic serum None 22 ( 15) P < 0.01 
Psoriatic serum Indomethacin 65 (9) 
(10 - 5 M) 
Psoriatic seru m .a-ca rotene 29 (13) jJ < 0.01 
(0.1 J.Lg/ml) 
Psoriatic serum SOD 63 (J3) 
Psoriatic serum Mercaptoethanol 69 (10) 
(2 X 10 - 5 M) 
Monocytes of psoriatic patients ( lOS/ wel l) were cultu red in the presence of 10 
IU / ",I IFN--y and either normal AB serum or auto logous seru", for 3 days. T he 
supplements were added o n day O. 
' Mea n (SD). n = 5. 
tried to detect disturbances in the production or fun ction of IFN-
y on psoriatic patients. 
The results show that an insuffi cient IFN-y synthesis by lym-
phocytes (Table I) and /o r a dimini shed IFN-y res po nse by mono-
cytes (Fig 2a) co uld not be the reason for the in vivo red uced DR 
antigen expression on monocyte~ of psoriatic patients. However, 
Fig 2b shows that the patients' sera contain a factor-or m aybe 
more-which neutralizes the effect ofIFN-y. Probably, this serum 
factor induces a state of diminished susceptibility to IFN-y. by 
raising the intracellular level of cAMP directly or indirectl y as 
described for lipopoly.saccharides. zy mosan, o r PGE [1 ,2.13]. 
Indeed. the cyClooxygenase inhibitor indo methacin prevented 
the inhibitory effect of these sera (Table II), and this could indicate 
that the induction of PG synthesis in the monocytes of psoriati c 
patients by their sera co uld be the cause of the inhibition of the 
DR antigen expression. Evidently, the IFN-y effect on monocytes 
of hea lth y don ors was only rarely affected by the sera of pso riat ic 
patients. O bviously, the monocytes of hea lth y volunteers are 
more resistant to the inhibitory signal med iated by the patients' 
sera and that can impl y that monocytes of psoriatic patients differ 
from those of no rmal persons in their functional state. 
The nature of th e inhibitory factor(s) is not clear. The serum-
mediated DR antigen inhibition ca n be prevei1ted by add ition of 
2-mercaptoethanol or SOD (Table II). This effect is of special 
int~res t as it im.plicatcs a mechanism analogous to the concana-
valin A-derived ,so luble immune response suppressor (SIRS), a 
55;000-dalton glycoprotein produced by concanavalin A-acti-
vated T cells which blocks antibody response and mitogen-in-
du ced pro liferation in vitro and in vivo [14.15] . It is rel eased by 
suppressor T cells in an inert precurso r form and is converted 
into the active moiety upon oxidation by H 20 2 derived from 
stimulated monocytes [14]. T he inhibito ry effect o f SIRS on var-
ious immune functions can be inhibited by reagents which sup-
press the formation of the monocyte-modified soluble factor 
(catalase, cyanide) or inactiva te it (~educing agents like 
2-mercaptoethario l) [14.15] . The SIRS ca n also induce PGE 
synthesis [14] . Remarkably , SIRS can be produced by T cells 
incubated with IFN-O' instead of cOllcariavaliri A [14]. 
Recently. IFN-Iike activity has been detected in bo th the skin 
and the blood of psoriati c patients [7.8]. The presence of IFN in 
the circul ation is possibly responsible for th e production of a 
SIRS-like lymphokii1e by the lymphocytes of patients; activated 
further by monocy tes, this active moiety is probably able to in-
duce PGE synthesis in monocytes. and that could provide us with 
an explanation for the decreased proportion of DR + monocytes 
in psoriat ic patients described above. Since similar defects in DR 
antigen expression on monocytes are observed in quite disparate 
conditions like systemic lupus erythematosus. infections with 
Mycobacterium leprae. sepsis. and psoriasis [1.16-18], it is quite 
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unlikely that they are the actual cause of the disease. The possi-
bility that a chronic inflammatory process so mehow leads to these 
effects is at least as likely. These observed phenomena may be 
the expression of an attempted contraregu lation against the au-
toimmune and/or chronic inflammatory process in the organism. 
An effective therapy of psoriasis co uld be 3n enhancement of the 
na tural regulatory processes, if we know more about them . At 
present, we are studying the mediators of biologic immuno-
suppression and the mechanisms of their induction. 
Experiments are in progress to investigate whether the effects 
described in this paper are also detectable in the skin (epiderma l 
cell culture, suction blister fluid). 
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